Daniel De Boer

Daniel is Founder and Chief Executive Officer of ProQR Therapeutics. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases, and raised approx $400M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings therapeutics, strategic advisor at Frame Therapeutics, Meatable and Algramo and a member of the board at the Termeer Foundation. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.

Daniel met Henri in late 2011, after stalking him for months to get a meeting. 6 months later they co-founded ProQR Therapeutics. Daniel had the privilege of working closely with Henri as a board member in the years after and benefit from his mentorship in building ProQR.